<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765189</url>
  </required_header>
  <id_info>
    <org_study_id>MNGEFS</org_study_id>
    <nct_id>NCT04765189</nct_id>
  </id_info>
  <brief_title>Evaluation of Mangoselect® in Improvement of Exercise/Activity-induced Knee Joint Discomfort in Subjects Suffering From Osteoarthritis Grade I or II</brief_title>
  <official_title>Evaluation of the Efficacy of Mangoselect®, a Mangosteen Extract, and of a Formulation Containing Mangoselect®, in Subjects Suffering From Activity/Exercise-induced Knee Joint Discomfort During a 12-week Supplementation Period. A Double-blind, Randomized, Multi-arm, Parallel and Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fytexia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fytexia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present investigation is to evaluate the efficacy of Mangoselect®, a&#xD;
      mangosteen extract, and of a formulation containing Mangoselect®, in subjects suffering from&#xD;
      activity/exercise-induced knee joint pain/discomfort, during a 12-week supplementation&#xD;
      period. Subjective discomfort improvement will be assessed with both WOMAC questionnaire and&#xD;
      pain Visual Analogic Scale (VAS); functional joints features, quality of life, and&#xD;
      inflammatory markers, will also be assessed. Finally, long lasting benefits will additionally&#xD;
      be evaluated 4 weeks after the end of the supplementation period. The design of the study is&#xD;
      double-blind, randomized, multi-arm, parallel and placebo controlled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in knee joint pain subscale from WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in knee joint subjective pain rating using a VAS (Visual Analog Scale) 0-10 cm</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in knee joint stifness subscale from WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in knee joint physical functionning subscale from WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in knee mobility assessed with ROM (Range of Motion) assessment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscular strength assessed with isokinetic strength measurment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status assessed with TNF-alpha plasma concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status assessed with TNF-alpha receptor R1 plasma concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status assessed with TNF-alpha receptor R2 plasma concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status assessed with IL-1beta plasma concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status assessed with IL-1beta receptor p68 plasma concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status assessed with IL-1beta receptor p80 plasma concentration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessed with SF-12 questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain killer drug consumption assessed with daily diary</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo product is 100% maltodextrin. Daily dosage is 500 mg in 2 capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Verum A</intervention_name>
    <description>Verum A is 200 mg of mangosteen extract. Daily dosage is 200 mg in 2 capsules.</description>
    <arm_group_label>Verum A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Verum B</intervention_name>
    <description>Verum B is 400 mg of mangosteen extract. Daily dosage is 400 mg in 2 capsules.</description>
    <arm_group_label>Verum B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Verum C</intervention_name>
    <description>Verum C is 200 mg mangosteen extract + 300 mg grape extract. Daily dosage is 500 mg in 2 capsules.</description>
    <arm_group_label>Verum C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Physically active volunteers&#xD;
&#xD;
          -  BMI 22-29.9 kg/m2&#xD;
&#xD;
          -  Declaring knee joint pain during and/or after activity/exercise&#xD;
&#xD;
          -  Joint knee pain rated of at least 4 cm on a 10 cm VAS following activity/exercise&#xD;
&#xD;
          -  Diagnosed osteoarthritis grade I or II according to Kellgren-Lawrence classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed inflammatory joint disorder or osteoarthritis grade III or more according to&#xD;
             Kellgren-Lawrence classification&#xD;
&#xD;
          -  Currentlu chronically taking pain killer drugs or dietary supplement or&#xD;
             intra-articular treatment 3 months before selection&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Subjects with knee/joint surgery/replacement in the past 10 years&#xD;
&#xD;
          -  Significant injury of the studied knee joint 12 months before selection&#xD;
&#xD;
          -  Unable to carry out functional tests and/or questionnaires&#xD;
&#xD;
          -  Currently participating or having participated in another clinical trial in the 3&#xD;
             previous months&#xD;
&#xD;
          -  Pregnant women and women positive at Beta-HCG serology test&#xD;
&#xD;
          -  Any condition that the investigator believes would interfere with the ability to&#xD;
             provide inform consent, or comply with study instructions, or confound the&#xD;
             interpretations of the study results, or put the volunteer at undue risk&#xD;
&#xD;
          -  Allergy to one of the component of the supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Alcaraz</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCAM (Universidad Catolica San Antonio de Murcia)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Cases</last_name>
    <phone>(+33) 467 219 098</phone>
    <email>jcases@fytexia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCAM (Universidad Catolica San Antonio de Murcia)</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda H Chung</last_name>
      <phone>(+34) 968 278 611</phone>
      <email>lhchung@ucam.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

